Gabelli Funds LLC Sells 3,900 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Gabelli Funds LLC cut its holdings in Henry Schein, Inc. (NASDAQ:HSICFree Report) by 1.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 364,686 shares of the company’s stock after selling 3,900 shares during the quarter. Gabelli Funds LLC’s holdings in Henry Schein were worth $27,078,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of HSIC. Baystate Wealth Management LLC grew its position in Henry Schein by 2,500.0% during the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the last quarter. West Tower Group LLC purchased a new position in Henry Schein in the 2nd quarter worth $44,000. Penserra Capital Management LLC acquired a new stake in Henry Schein during the 2nd quarter worth about $68,000. Covestor Ltd grew its stake in Henry Schein by 88.4% during the 1st quarter. Covestor Ltd now owns 861 shares of the company’s stock valued at $75,000 after purchasing an additional 404 shares during the last quarter. Finally, RVW Wealth LLC purchased a new position in shares of Henry Schein in the third quarter worth about $104,000. Hedge funds and other institutional investors own 93.31% of the company’s stock.

Henry Schein Stock Down 1.6 %

NASDAQ HSIC opened at $74.91 on Tuesday. The business’s fifty day simple moving average is $73.54 and its 200-day simple moving average is $73.09. The company has a quick ratio of 1.09, a current ratio of 1.97 and a debt-to-equity ratio of 0.42. The firm has a market cap of $9.73 billion, a PE ratio of 22.29, a P/E/G ratio of 2.50 and a beta of 0.87. Henry Schein, Inc. has a 52 week low of $60.01 and a 52 week high of $89.60.

Henry Schein (NASDAQ:HSICGet Free Report) last posted its quarterly earnings results on Monday, November 13th. The company reported $1.32 earnings per share for the quarter, meeting the consensus estimate of $1.32. The business had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $3.21 billion. Henry Schein had a net margin of 3.51% and a return on equity of 16.08%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.56 earnings per share for the current year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 11,238 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $74.02, for a total value of $831,836.76. Following the sale, the chief executive officer now owns 57,831 shares of the company’s stock, valued at $4,280,650.62. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Henry Schein news, CEO Bradford C. Connett sold 11,238 shares of Henry Schein stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $74.02, for a total value of $831,836.76. Following the completion of the transaction, the chief executive officer now directly owns 57,831 shares of the company’s stock, valued at approximately $4,280,650.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Stanley M. Bergman sold 13,962 shares of the business’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $75.14, for a total transaction of $1,049,104.68. Following the sale, the chief executive officer now owns 168,633 shares in the company, valued at $12,671,083.62. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HSIC shares. Morgan Stanley dropped their price objective on shares of Henry Schein from $69.00 to $65.00 and set an “underweight” rating on the stock in a report on Tuesday, November 14th. JPMorgan Chase & Co. upgraded Henry Schein from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $71.00 to $82.00 in a research report on Tuesday, December 12th. Piper Sandler reduced their price target on shares of Henry Schein from $94.00 to $84.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. UBS Group decreased their target price on Henry Schein from $82.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 14th. Finally, StockNews.com lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Monday, December 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Henry Schein has a consensus rating of “Moderate Buy” and a consensus price target of $79.25.

Get Our Latest Stock Report on HSIC

About Henry Schein

(Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Read More

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSICFree Report).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.